CY1117835T1 - Υδατικες φαρμακευτικες συνθεσεις που περιεχουν συμπλοκα βορικου - πολυολης - Google Patents

Υδατικες φαρμακευτικες συνθεσεις που περιεχουν συμπλοκα βορικου - πολυολης

Info

Publication number
CY1117835T1
CY1117835T1 CY20161100735T CY161100735T CY1117835T1 CY 1117835 T1 CY1117835 T1 CY 1117835T1 CY 20161100735 T CY20161100735 T CY 20161100735T CY 161100735 T CY161100735 T CY 161100735T CY 1117835 T1 CY1117835 T1 CY 1117835T1
Authority
CY
Cyprus
Prior art keywords
polyolis
aquatic
complexes
pharmaceutical compositions
compositions containing
Prior art date
Application number
CY20161100735T
Other languages
English (en)
Inventor
Bhagwati P Kabra
Original Assignee
Alcon Research, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42364357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117835(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Research, Ltd. filed Critical Alcon Research, Ltd.
Publication of CY1117835T1 publication Critical patent/CY1117835T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά στην παροχή οφθαλμικών συνθέσεων πολλαπλής δόσης. Οι συνθέσεις έχουν επαρκή αντιμικροβιακή δραστικότητα για να ικανοποιούν τις απαιτήσεις αποτελεσματικότητας συντηρητικού USP, καθώς επίσης και άλλα παρόμια πρότυπα συντηρητικών (π.χ., ΕΡ και JP). Οι συνθέσεις περιλαμβάνουν δύο διαφορετικές πολυόλες σε συνδυασμό με το βορικό άλας και μια χαμηλή συγκέντρωση χλωριούχου βενζαλκονίου.
CY20161100735T 2009-06-19 2016-07-26 Υδατικες φαρμακευτικες συνθεσεις που περιεχουν συμπλοκα βορικου - πολυολης CY1117835T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21847209P 2009-06-19 2009-06-19
EP10727317.9A EP2442790B1 (en) 2009-06-19 2010-06-17 Aqueous pharmaceutical compositions containing borate-polyol complexes

Publications (1)

Publication Number Publication Date
CY1117835T1 true CY1117835T1 (el) 2017-05-17

Family

ID=42364357

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100735T CY1117835T1 (el) 2009-06-19 2016-07-26 Υδατικες φαρμακευτικες συνθεσεις που περιεχουν συμπλοκα βορικου - πολυολης
CY20201100637T CY1123120T1 (el) 2009-06-19 2020-07-10 Υδατικες φαρμακευτικες συνθεσεις που περιεχουν συμπλοκα βορικου-πολυολης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100637T CY1123120T1 (el) 2009-06-19 2020-07-10 Υδατικες φαρμακευτικες συνθεσεις που περιεχουν συμπλοκα βορικου-πολυολης

Country Status (27)

Country Link
US (3) US9044484B2 (el)
EP (4) EP3437634A1 (el)
JP (3) JP6017956B2 (el)
KR (1) KR101738502B1 (el)
CN (2) CN104707145A (el)
AR (2) AR077126A1 (el)
AU (1) AU2010262898B2 (el)
BR (1) BRPI1015996B8 (el)
CA (1) CA2763778C (el)
CL (1) CL2010000634A1 (el)
CY (2) CY1117835T1 (el)
DK (3) DK2722035T3 (el)
ES (3) ES2584858T3 (el)
HK (2) HK1194007A1 (el)
HR (2) HRP20160953T1 (el)
HU (2) HUE049477T2 (el)
LT (1) LT3045164T (el)
MX (1) MX2011013107A (el)
PL (3) PL2442790T3 (el)
PT (3) PT3045164T (el)
RU (1) RU2563125C2 (el)
SI (3) SI2442790T1 (el)
SM (1) SMT201600249B (el)
TW (1) TWI489997B (el)
UY (1) UY32709A (el)
WO (1) WO2010148190A1 (el)
ZA (1) ZA201108384B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101541303B1 (ko) * 2008-03-17 2015-08-03 알콘 리서치, 리미티드 보레이트-폴리올 복합체를 함유하는 수성 약학적 조성물
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
CN103379904A (zh) * 2011-01-18 2013-10-30 千寿制药株式会社 具有保存效能的溴芬酸水性液剂组合物
US20120269862A1 (en) 2011-04-22 2012-10-25 Chowhan Masood A Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents
EP2699229A2 (en) 2011-04-22 2014-02-26 Alcon Research, Ltd. Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents
US20120312840A1 (en) * 2011-05-13 2012-12-13 Ayako Hasegawa Container closure system with integral antimicrobial additives
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
PT2950648T (pt) 2013-02-01 2020-01-06 Ocuphire Pharma Inc Soluções oftálmicas aquosas de fentolamina e usos médicos
WO2014121028A1 (en) 2013-02-01 2014-08-07 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
BR112016003692B1 (pt) 2013-08-20 2022-02-08 3M Innovative Properties Company Complexo poliéter boro-silano
JP6247430B1 (ja) * 2016-06-15 2017-12-13 千寿製薬株式会社 眼科用医薬製品
WO2017217450A1 (ja) * 2016-06-15 2017-12-21 千寿製薬株式会社 眼科用医薬製品
CN106237337B (zh) * 2016-08-05 2019-11-08 河南中帅医药科技股份有限公司 一种液体药物制剂用防腐组合物
GR1009419B (el) * 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
JP7413040B2 (ja) 2018-02-21 2024-01-15 三菱重工サーマルシステムズ株式会社 スクロール流体機械及びその設計方法
KR20210096096A (ko) 2018-10-26 2021-08-04 오큐파이어 파마, 인크. 노안, 산동, 및 기타 안구 장애의 치료를 위한 방법 및 조성물
JP7021301B2 (ja) 2019-07-23 2022-02-16 ニコックス アフサァルミィクス、 インコーポレイテッド 無菌眼用水性プロピオン酸フルチカゾンａ型ナノ結晶懸濁液の調製方法
EP4142689A1 (en) 2020-04-29 2023-03-08 Sentiss Pharma Private Limited Ophthalmic compositions comprising a combination of brinzolamide and brimonidine
US11850249B2 (en) 2020-10-05 2023-12-26 Somerset Therapeutics, Llc Methods of efficiently reducing intraocular pressure
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
GB2084870B (en) 1980-10-10 1985-05-09 Muhlemann R Hans Oral compositions containing pyrimidine amine compounds and zinc salts
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5221664A (en) 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
JP3058656B2 (ja) 1990-06-18 2000-07-04 トーメー産業株式会社 コンタクトレンズ用液剤組成物及びそれを用いたコンタクトレンズの洗浄若しくは保存方法
KR0127768B1 (ko) 1990-12-27 1997-12-26 마틴 에이. 보에트 콘택트렌즈를 살균하기 위한 방법 및 조성물
US5460834A (en) 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
JP2873530B2 (ja) * 1991-12-13 1999-03-24 参天製薬株式会社 ニュートン型粘性を示すカルボキシビニルポリマー含有点眼液基剤
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
WO1993021903A1 (en) 1992-05-06 1993-11-11 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
US5320843A (en) 1992-12-10 1994-06-14 Polymer Technology Corporation Method for improving antibacterial properties of ophthalmic solutions
CA2088927A1 (en) 1993-02-11 1994-08-12 Donald Skeffington Preservative system for vitamin e aqueous solution
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
TW274516B (el) 1993-11-12 1996-04-21 Ciba Geigy Ag
AU3070395A (en) 1994-07-22 1996-02-22 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US5603929A (en) 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US6024954A (en) 1994-12-12 2000-02-15 Allergan Compositions and methods for disinfecting contact lenses and preserving contact lens care products
US6011062A (en) 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
CN1074277C (zh) 1995-03-20 2001-11-07 尤尼利弗公司 液体洁肤制剂
US5683993A (en) 1995-06-22 1997-11-04 Ciba Vision Corporation Compositions and methods for stabilizing polymers
HU225329B1 (en) 1996-09-12 2006-09-28 Richter Gedeon Vegyeszet Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity
AU4428397A (en) 1996-09-20 1998-04-14 Warner-Lambert Company Oral compositions containing a zinc compound
US5820822A (en) 1996-10-25 1998-10-13 Kross; Robert D. Antimicrobial composition and method of use
JPH10130156A (ja) 1996-10-30 1998-05-19 Teika Seiyaku Kk 点眼剤組成物
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
DE69735963T2 (de) 1996-12-13 2007-01-25 Alcon Laboratories, Inc., Fort Worth Aminoalkohole enthaltende ophthalmische Zusammensetzungen
US5858346A (en) 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
US6265444B1 (en) * 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
CN1229110C (zh) 1997-07-29 2005-11-30 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
WO2004073708A1 (en) 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US6034043A (en) 1999-04-20 2000-03-07 Lever Brothers Company, Division Of Conopco, Inc. Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6166012A (en) 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
JP4322503B2 (ja) 2000-11-29 2009-09-02 ノバルティス アクチエンゲゼルシャフト 水性消毒系
AR035509A1 (es) 2000-12-21 2004-06-02 Alcon Inc Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento
JP4844706B2 (ja) 2001-03-12 2011-12-28 ライオン株式会社 眼科用組成物
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
JP4863589B2 (ja) 2001-09-28 2012-01-25 ロート製薬株式会社 水性組成物
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
TWI322828B (en) 2002-12-23 2010-04-01 Alcon Inc Use of multifunctional surface active agents to clean contact lenses
WO2004064828A1 (ja) * 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤
US7445771B2 (en) 2003-12-09 2008-11-04 Alcon, Inc. Use of bis-amines to enhance the antimicrobial activity of aqueous compositions
US20050124702A1 (en) 2003-12-09 2005-06-09 Alcon, Inc. Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions
WO2005060933A1 (en) 2003-12-11 2005-07-07 Alcon, Inc. Ophthalmic compositions containing a polysaccharide/borate gelling system
US20050214382A1 (en) 2004-03-29 2005-09-29 Erning Xia Zinc preservative composition and method of use
JP2008515982A (ja) * 2004-10-13 2008-05-15 メルク エンド カムパニー インコーポレーテッド 高眼圧症を治療するための眼科組成物
US20060229219A1 (en) * 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
US20070212420A1 (en) 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
US20070297990A1 (en) 2006-06-27 2007-12-27 Shah Mandar V Self-preserving composition
WO2008002118A1 (es) 2006-06-27 2008-01-03 Arturo Jimenez Bayardo Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
ZA200901164B (en) * 2006-09-21 2010-06-30 Alcon Res Ltd Self preserved aqueous pharmaceutical compositions
JP5394927B2 (ja) 2006-09-28 2014-01-22 アルコン リサーチ， リミテッド 自己保存性水性医薬品組成物
US20080095863A1 (en) 2006-10-24 2008-04-24 Alcon Manufacturing Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
US20080093247A1 (en) 2006-10-24 2008-04-24 Alcon Manufacturing Ltd. Packaging materials for formulations containing 2-pyrrolidone derivatives
US7705112B2 (en) 2007-04-17 2010-04-27 Abbott Medical Optics Inc. Polyquaternium-1 synthesis methods
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
KR101541303B1 (ko) 2008-03-17 2015-08-03 알콘 리서치, 리미티드 보레이트-폴리올 복합체를 함유하는 수성 약학적 조성물
US7999064B2 (en) 2009-04-23 2011-08-16 Abbott Medical Optics Inc. Polyquaternium-1 synthesis methods and associated formulations
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物

Also Published As

Publication number Publication date
PT2442790E (pt) 2014-05-12
UY32709A (es) 2010-12-31
KR20120028390A (ko) 2012-03-22
EP3437634A1 (en) 2019-02-06
JP6017956B2 (ja) 2016-11-02
JP2014198729A (ja) 2014-10-23
CA2763778C (en) 2016-02-02
EP2442790B1 (en) 2014-03-26
PT3045164T (pt) 2020-07-14
JP2012530712A (ja) 2012-12-06
HRP20200979T1 (hr) 2020-10-16
EP2442790A1 (en) 2012-04-25
SI2722035T1 (sl) 2016-09-30
PT2722035T (pt) 2016-08-02
MX2011013107A (es) 2012-01-20
RU2012101782A (ru) 2013-07-27
ES2803648T3 (es) 2021-01-28
BRPI1015996B8 (pt) 2021-05-25
HUE049477T2 (hu) 2020-09-28
AR122017A2 (es) 2022-08-03
CN102802604B (zh) 2016-02-10
PL2722035T3 (pl) 2016-11-30
SI2442790T1 (sl) 2014-05-30
DK2442790T3 (da) 2014-04-14
US20160324967A1 (en) 2016-11-10
CA2763778A1 (en) 2010-12-23
HUE030435T2 (en) 2017-05-29
EP2722035A1 (en) 2014-04-23
CN104707145A (zh) 2015-06-17
DK2722035T3 (en) 2016-08-01
DK3045164T3 (da) 2020-07-13
TWI489997B (zh) 2015-07-01
HRP20160953T1 (hr) 2016-10-07
EP2722035B1 (en) 2016-04-27
ES2584858T3 (es) 2016-09-29
BRPI1015996A8 (pt) 2018-01-09
WO2010148190A1 (en) 2010-12-23
CL2010000634A1 (es) 2011-03-11
AR077126A1 (es) 2011-08-03
HK1194007A1 (zh) 2014-10-10
BRPI1015996A2 (pt) 2016-04-26
SI3045164T1 (sl) 2020-08-31
SMT201600249B (it) 2016-08-31
CY1123120T1 (el) 2021-10-29
US20150224196A1 (en) 2015-08-13
PL3045164T3 (pl) 2020-10-19
US9421265B2 (en) 2016-08-23
TW201100103A (en) 2011-01-01
AU2010262898B2 (en) 2015-02-12
LT3045164T (lt) 2020-07-27
EP3045164A1 (en) 2016-07-20
BRPI1015996B1 (pt) 2020-08-11
CN102802604A (zh) 2012-11-28
AU2010262898A1 (en) 2011-12-15
US20100324031A1 (en) 2010-12-23
ES2461617T3 (es) 2014-05-20
US9044484B2 (en) 2015-06-02
HK1163521A1 (en) 2012-09-14
PL2442790T3 (pl) 2014-08-29
JP2016183198A (ja) 2016-10-20
KR101738502B1 (ko) 2017-05-22
RU2563125C2 (ru) 2015-09-20
ZA201108384B (en) 2013-01-30
EP3045164B1 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
CY1117835T1 (el) Υδατικες φαρμακευτικες συνθεσεις που περιεχουν συμπλοκα βορικου - πολυολης
CY1114712T1 (el) Υδατικες φαρμακευτικες συνθεσεις περιεχουσες συμπλοκα βορικου-πολυολης
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
CY1115844T1 (el) Μακροκυκλικοι αναστολεις της πρωτεασης σερινης της ηπατιτιδας c
NZ588999A (en) Compositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof
CR10027A (es) Nuevos derivados de pirrol fusionado
BRPI0520014A2 (pt) emulsões oftálmicas estáveis de óleo-em-água com hialuronato de sódio para alìvio de olho seco
CY1112138T1 (el) Αυτο-συντηρημενες υδατικες φαρμακευτικες συνθεσεις
EA201070597A1 (ru) Антибактериальные аналоги аминогликозида
GT200600028A (es) Compuestos y composiciones como inhibidores de proteina kinasa
CO6341526A2 (es) Povidona yodada, un preservativo alternativo novedoso para composiciones oftalmologicas
BR112013002144A2 (pt) compostos para o tratamento e/ou a prevenção de doeças inflamatórias oculares
EA201390799A1 (ru) Триазолопиридины
UY32731A (es) Nuevos derivados de piperidin-ilidenaminooxi-piperidin, composiciones farmacéuticas y métodos relacionados con ellos
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
CY1110097T1 (el) Διπλοστοιβαδικο δισκιο για προληψη καρδιαγγειακων συμβαντων
CR20110190A (es) Agente rodenticida sinérgico
EA201201239A1 (ru) Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением
CR20120146A (es) Derivados de espirolactama y usos de los mismos
CR20120521A (es) Combinaciones de principios activos
AR092691A1 (es) Composicion farmaceutica que comprende rebamipida
BR112012013319A2 (pt) derivados espiro azacíclicos
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion